Latest information on COVID-19
Support teaching, research, and patient care.
Detlef Obal, MD, PhD, DESA is an Assistant Professor in the Department of Anesthesiology, Perioperative, and Pain Medicine. He is also a Member of the Stanford Cardiovascular Institute. Dr. Obal completed his medical training at the Universities of Manchester (UK), Pretoria (South Africa) and Düsseldorf (Germany). Dr. Obal earned his MD/PhD degree from the Heinrich-Heine University of Düsseldorf, Germany and his PhD degree from the University of Louisville, KY. His previous work focuses on multiple aspects of cardiac regeneration under the influence of different anesthetics and cardioprotective strategies (i.e. pre- and postconditioning) using different transgenic mouse models. He completed his postdoctoral training at the Stanford Cardiovascular Institute (Laboratory of Joseph Wu) at which he studied the effects of opioids on the cardiovascular system, using inducible pluripotent stem cells (iPSC) derived cardiomyocytes and endothelial cells.His laboratory focuses on improving anesthesia care by focusing on individuals’ phenotypical and genetic background. The major areas of interest of his laboratory are understanding the basic mechanism of G-protein coupled receptor signaling on iPSC-derived cardiac and endothelial cells (in collaboration with the Brian Kobilka and Steven Chu labs) and describing the effect of anesthetics on early cardiovascular development.Dr. Obal received multiple awards including the best poster price of the European Society of Anaesthesiology, Stanford Cardiovascular Institute Seed Grant, and the Stanford Maternal & Child Health Research Institute’s (MCHRI) TIP grant.Dr. Obal is a Board-Certified Anesthesiologist and a Diplomate of the European Society of Anaesthesiology (DESA) with a clinical commitment of 20% of his time.
I am primarily working at the Cardiovascular Institute (Director Joseph Wu, MD, PhD), studying the effect of different anesthetics on human induced pluripotent stem cells (hiPSC). Considering the current opioid epidemic, I am currently focusing on the effect of chronic opioid exposure on endothelial and cardiac function.
Use of New Supraglottic Airway Devices in Severely Obese Patients: A Feasibility Study
The purpose of this study is to determine whether two new airway devices used during
anesthesia called iGEL™ and KING-LTS-DTM work well and are safe in obese patients. They both
work well in thin patients, but have not been tested in obese patients.
Stanford is currently not accepting patients for this trial.
For more information, please contact SPECTRUM, .
View full details
EcoAnaesthesia Facemask Versus Standard Facemask During Anesthesia Induction
This study will evaluate the efficiency of the EcoAnesthesia mask and its advantages over the
standard facemask used in our practice. The satisfaction by the anesthesia provider and its
ease of use may change the standard practice in airway management. In addition to these
additional effects on patient safety, the facemask is affordable and may reduce the
environmental burden of anesthesia waste.
The ENIGMA II Trial:Nitrous Oxide Anaesthesia and Cardiac Morbidity After Major Surgery: a Randomised Controlled Trial
To investigate the safety of nitrous oxide (N2O) anaesthesia in patients with risk factors
for coronary artery disease undergoing major surgery.
As a translational scientist, I am interested in combining clinical data with patient specific characteristics to optimize anesthesia care. With the advantages in human genetics and tools like human inducible stem cells, I am trying to understand patients' specific needs and reactions to anesthetics, so that we will be able to provide individualized anesthesia care in the future.